ODI Pharma achieved market share targets in 2024 and increases its targets for 2025. Positioned for growth as Poland's medical cannabis market expands.
ODI Pharma AB ("ODI" or the "Company") provides an update on Poland’s expanding medical cannabis market, which remains an important focus of the Company’s strategy. Recent regulatory changes in Poland highlight ODI’s established position in one of Europe’s most promising markets for medical cannabis.With ODI Pharma’s sales during the current calendar year, ODI Pharma reached it’s previously stipulated goal of achieving a substantial market share of more than 10%, resulting in a positive operational result for the shareholders of ODI for the financial year 2023/2024. ODI Pharma has